Talphera TLPH 深 沪
等待开盘 10-16 09:30:00 美东时间
1.07
+0.010
+0.94%
华盛通- 最 高1.0866
- 今 开1.06
- 成交量 3.51万股
- 最 低 1.06
- 昨 收 1.06
- 总市值 5553.92万
- 52周最高 1.57
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 0.6866
- 委 比 84.28%
- 总股本 5190.58万
- 历史最高 272.80
- 量 比 0.39
- 振 幅 2.51%
- 历史最低 0.38
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Talphera Q2 EPS $(0.06) Beats $(0.07) Estimate
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year.
08-13 04:08
美股大行评级 | Ciena、Rubrik获多家大行上调目标价；库珀医疗、Guidewire软件、露露乐蒙等遭多家大行下调目标价
今日重点评级关注：瑞银：维持DraftKings"买入"评级，目标价从43美元升至49美元；Needham：维持Planet Labs"买入"评级，目标价从40美元升至53美元
06-08 11:33
HC Wainwright & Co. Assumes Talphera at Buy, Announces Price Target of $3
HC Wainwright & Co. analyst Brandon Folkes assumes Talphera (NASDAQ:TLPH) with a Buy rating and announces Price Target of $3.
06-05 20:42
Talphera Q1 2026 Earnings Call Transcript
Talphera (NASDAQ:TLPH) reported first-quarter financial results on Wednesday. T...
05-14 05:40
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
WestPark Capital Initiates Coverage On Talphera with Buy Rating, Announces Price Target of $3
WestPark Capital analyst Ed Arce initiates coverage on Talphera (NASDAQ:TLPH) with a Buy rating and announces Price Target of $3.
05-01 02:33
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 98.6% to $0.3...
04-08 20:05
Talphera Q4 EPS $(0.06) Beats $(0.14) Estimate
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is a 14.29 percent increase over losses of $(0.07) per share from the same
03-23 20:43
Talphera Announces 50% Patient Enrollment Of NEPHRO-CRRT Clinical Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring
03-02 21:40
